The thyrotropin receptor (TSHR), one of the primary antigens in autoimmune thyroid disease, is a target of both antigen-specific T cells and antibodies in patients with this condition (1) . Autoantibodies to the TSHR (TSHR-Ab) act as thyroid stimulating factor (TSH) agonists in autoimmune hyperthyroidism (Robert Graves disease) but as TSH antagonists in autoimmune hypothyroidism (Hashimoto thyroiditis). The TSHR antigen is primarily expressed in the epithelial cells of the thyroid follicles, but TSHR mRNA and protein have been reported in a variety of cell types, some of which show evidence of receptor activity ( Table 1) .
The TSHR gene, cloned in 1989 (2-5), maps to human chromosome 14q and encodes a predicted seventransmembrane, G protein-coupled glycoprotein. Although it is similar to the luteinizing hormone receptor and the follicle-stimulating hormone receptor, the TSHR is the largest of the glycoprotein hormone receptors, due primarily to 8-and 50-amino acid insertions in its ectodomain (residues 38-45 and 317-367) (6) . As predicted from its cDNA, the TSHR has an unglycosylated molecular weight of 84 kDa but the glycosylated holoreceptor runs on SDS-PAGE with an apparent molecular weight of 95-100 kDa. There are six potential N-linked glycosylation sites on the TSHR, and it was recently shown that the TSHR is also palmitoylated (7) . The minimal 5′ promoter region required to confer thyroid-specific expression and cAMP autoregulation extends from 220 to 39 bp upstream of the transcription start site, but there are multiple transcription start sites between -89 and -68 bp (8) .
TSHR signal transduction, regulation, and maturation
The TSHR, long known to signal via cAMP (9) , can induce both the phospholipase C (PLC) and the protein kinase A signal transduction systems. Intracellular Ca 2+ and PLC regulate iodide efflux, H 2 O 2 production, and thyroglobulin iodination, while adenylate cyclase and cAMP regulate iodide uptake and transcription of thyroglobulin (Tg), thyroid peroxidase (TPO), and the sodium-iodide symporter (10, 11) . Photoaffinity labeling of the TSHR with azido-GTP followed by immunoprecipitation suggests that all four Gα subtypes are involved (12) , but only Gα s and Gα q have been shown to mediate TSHR signals.
TSHR levels are positively regulated by TSH in normal cells (13) , secondary to prolongation of the mRNA halflife, while exposure to high concentrations of ligand causes the receptors to be downregulated (14) . Posttranslational proteolysis clips the TSH receptor (TSHR) into two subunits (referred to as α, or A, and β, or B) (15, 16) , linked to each other by disulfide bonds. These α and β subunits are formed by intramolecular cleavage, apparently at multiple sites, with removal of an intervening polypeptide segment of approximately 50 amino acids (amino acids 317-367) (17, 18) . Disulfide bonds that link the two subunits are then reduced, presumably by protein disulfide isomerase leading to release of the α subunit from the membrane-bound receptor (17, 19) . This phenomenon of releasing the α subunit is referred to as receptor shedding and explains the approximately 3:1 excess of β subunits found in thyroid membrane preparations (20) . These observations also explain the early data indicating that the long-acting thyroid stimulator (LATS) activity in Graves patients' sera, now attributed to activating TSHR-Ab's autoantibodies, can be absorbed using the supernatant from frozen and thawed thyroid tissues (21) . Moreover, such ectodomain shedding may also account for the puzzling size diversity of TSHRs detected by Western blot (20) . Crucially, shedding also leads to a structural change in the α subunit once it is released from the receptora change whose consequences are considered by Chazenbalk et al. in this issue of the JCI (22) .
Commentary
See related article, pages 209-217. Recent work from our laboratory has demonstrated that the TSH receptor is constitutively oligomeric (27) . labeled TSHR constructs, we confirmed the presence of TSHR multimers in cell membranes, as we previously suggested based on molecular size (20) . We have now also found that these oligomeric forms rapidly dissociate upon TSH binding (28) (Figure  2 ), indicating that ligand binding alters the shape of the receptor, promoting dissociation of the oligomeric receptors into active, open monomers. Moreover, murine monoclonal TSHR antibodies, which block TSH action, fail to mimic TSH or to promote TSHR monomer formation (R. Latif et al., unpublished data). If, as we suggest, the monomeric form of the TSHR can be recruited more efficiently into lipid rafts (29) than can the larger complexes, these observations may indicate a mechanism by which the monomer preferentially couples with G proteins (30) to initiate signaling ( Figure 2 ). Although stimulating TSHR-Ab's are unique to patients with Graves disease, their serum has been shown to most commonly contain a mixture of both blocking and stimulating TSHR-Ab's (1), and the bioactivity of the serum reflects a balance between the two. Unfortunately, the surprising failure of many investigators to isolate high-affinity monoclonal stimulating TSHR antibodies represents a major impediment to understanding the basis of this response. Nevertheless, we hypothesize that stimulating, but not blocking, TSHRAb's lead to the formation of TSHR dimers, which may still be able to move into the lipid rafts and initiate signal transduction (Figure 2 ). While monomers can move quickly within the lipid rafts, as shown by fluorescence recovery after photobleaching experiments, movement of dimeric receptors within the rafts is predicted to be slower, perhaps accounting for the relatively weak but prolonged signaling that results from exposure to LATS sera (31) .
The failure to obtain monoclonal stimulating antibodies of high affinity to the TSHR remains a great enigma in modern thyroid research. While blame has always been assigned to insensitive detection systems combined with a small repertoire of TSHR-Ab-secreting B cells, it is also possible that the state of the TSHR, not just the nature of the antibody, determines whether antibody binding can activate signaling. Combinations of TSHR-Ab's, which on their own may not activate the receptor, may be required to shift the receptor into an activated form -perhaps by promoting TSHR monomer formation. This hypothesis is eminently testable and promises more excitement in this rapidly developing field.
